Healthcare shares are flat to higher in pre-market trade.
) says it has planned a public offering, though it did not provide
the details on the number or shares or share price. TKMR is flat in
pre-market at $8.82.
And, Amarin Corporation (
) is down sharply this morning after the FDA's Endocrinologic and
Metabolic Drugs Advisory Committee voted 9 to 2 against approval of
Vascepa. The FDA is scheduled to make its decision on whether to
approve the ANCHOR Supplemental New Drug Application (sNDA) on the
December 20, 2013 Prescription Drug User Fee Act goal date for the
UnitedHealth Group (
) is down more than 3% after it reported Q3 earnings of $1.53 per
share, in line with the Capital IQ consensus. Revenues were $30.62
billion, versus the analyst estimate of $30.89 billion.
The company now expects FY13 EPS of $5.40 - $5.50, revised from
the prior guidance of $5.35 - $5.50, and versus the Street view of
$5.51; it reaffirmed its revenue outlook of $122 billion versus the
consensus of $123.11 billion.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.